Friday, July 10, 2026

pharma · Head and Neck Neoplasms · Rheumatoid Arthritis

Chinese University of

Chinese University of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Head and Neck Neoplasms, Rheumatoid Arthritis, Rare Tumor, Essential Hypertension, Primary Esophageal Motility D

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
42
Drugs
55
Patents
0
Clinical program

Cisplatin and Doxorubicin

Phase 2 · small molecule · Gastric Cancer Peritoneal Metastases

Cisplatin and Doxorubicin for Gastric Cancer Peritoneal Metastases is a Phase 2 program (small_molecule) at Chinese University of Hong Kong with 1 ClinicalTrials.gov record(s).

Internal code 2020.677

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Chinese University of Hong Kong
Phase
Phase 2
Modality
small_molecule
Indication
Gastric Cancer Peritoneal Metastases
Status
active
Trials
1